Holen Sie sich die Stockscreener-App
0.5248
4.58%
-0.0252
Handel nachbörslich:
.52
-0.0048
-0.91%
Schlusskurs vom Vortag:
$0.55
Offen:
$0.543
24-Stunden-Volumen:
75,097
Relative Volume:
0.11
Marktkapitalisierung:
$32.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-0.4485
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
-6.29%
1M Leistung:
-14.94%
6M Leistung:
-29.72%
1J Leistung:
-57.68%
1-Tages-Spanne:
$0.5202
$0.565
1-Wochen-Bereich:
$0.5202
$0.5917
52-Wochen-Spanne:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.5248 | 32.42M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Passage Bio Inc to Host Earnings Call - ACCESS Newswire
Passage Bio (NASDAQ:PASG) versus SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head Review - Defense World
Passage Bio will again trim workforce in latest cost-cutting move - The Business Journals
Passage Bio CFO sells shares worth $1,685 - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Passage Bio CFO sells shares worth $1,685 By Investing.com - Investing.com UK
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued - BioSpace
Passage Bio shares transition to Nasdaq Capital Market - MSN
Passage Bio shares transition to Nasdaq Capital Market By Investing.com - Investing.com South Africa
TELA Bio Grants Inducement Stock Units to New Employees - MyChesCo
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):